DOCSLIB.ORG

Email: [email protected] AC-001 154235-83-3 Ampalex AC-002 34381-68-5 Acebutolol Hydrochloride AC-003 5438-68-6 O-Acetyl Ma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Email: Sales@Apichemistry.Com AC-001 154235-83-3 Ampalex AC-002 34381-68-5 Acebutolol Hydrochloride AC-003 5438-68-6 O-Acetyl Ma Email: [email protected] Catalog No. CAS No. Product Name AC-001 154235-83-3 Ampalex AC-002 34381-68-5 Acebutolol Hydrochloride AC-003 5438-68-6 O-acetyl mandelic acid AC-004 5080-50-2 Acetyl-L-Carnitine Hydrochloride AC-006 61985-25-9 4-Acetylimidazole AC-007 57756-36-2 4-Acetyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine AC-008 99-96-7 4-Hydroxybenzoic acid AC-009 51037-30-0 Acipimox AC-011 39269-10-8 1,3-Adamantanedicarboxylic acid AC-012 106941-25-7 Adefovir AC-013 50-42-0 Adiphenine Hydrochloride AC-014 56-41-7 L-Alanine AC-015 54965-21-8 Albendazole AC-016 54029-12-8 Albendazole Sulfoxide AC-017 26750-81-2 Alibendol AC-018 80863-62-3 Alitame AC-019 315-30-0 Allopurinol AC-020 481-72-1 Aloeemodin AC-021 850649-62-6 Alogliptin Benzoate AC-022 122852-69-1 Alosetron Hydrochloride AC-023 850-52-2 ALTRENOGEST AC-024 23828-92-4 Ambroxol Hydrochloride AC-025 1750-42-1 3-Aminoisoxazole AC-026 149934-21-4 9-Amino-minocycline hydrochloride AC-027 98-16-8 M-amino trifluorotoluene AC-028 455-14-1 4-Aminobenzotrifluoride AC-029 55716-66-0 4-aminobenzocyclobutene AC-030 126325-50-6 3-Amino-2-bromo-4-picoline AC-031 1072-97-5 2-Amino-5-bromopyridine AC-032 84249-14-9 2-Amino-4-bromopyridine AC-033 96-20-8 2-Amino-1-butanol AC-034 13325-10-5 4-Amino-1-butanol AC-035 60-32-2 6-Aminocaproic acid AC-036 121-30-2 4-Amino-6-chloro-benzene-1,3-disulfonic acid diamide AC-037 95-24-9 2-Amino-6-chlorobenzothiazole Hangzhou APIChem Technology Co., Ltd. Email:[email protected]:www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-038 20776-67-4 2-Amino-5-chloro-3-methylbenzoic acid AC-039 3993-78-0 2-Amino-4-Chloropyrimidine AC-040 3814-46-8 2-Aminocycloheptanecarboxylic acid AC-041 75081-40-2 (±)-2-Amino-cyclohexanecarboxylic acid AC-042 27489-62-9 trans-4-Aminocyclohexanol AC-043 156732-15-9 (2S,3S,5S)-5-amino-2-(dibenzylamino)-1,6-diphenyl hexan-3-ol AC-044 120068-79-3 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cycano pyrazole AC-045 43024-15-3 3-Amino-4-ethylpyrazole AC-046 344-80-9 2-Amino-2'-fluoro-5-nitrobenzophenone AC-047 2247-88-3 4-Amino-3-fluoropyridine AC-048 73616-27-0 5-Amino-1-(2-hydroxyethyl)pyrazole AC-049 2280-48-0 (R)-2-Amino-3-Hydroxy-3-Methylbutanoic Acid AC-050 6320-39-4 3-Amino-4-hydroxypyridine AC-051 7720-39-0 2-aminoimidazole AC-052 6967-12-0 6-Amino-1H-indazole AC-053 129488-10-4 5-Amino-1H-indazole-1-carboxylic acid, 1,1 dimethyl ethyl ester AC-054 106-60-5 5-Aminolevulinate AC-055 3880-88-4 2-amino-5-methoxytetralin Hydrochloride AC-056 2840-04-2 5-Amino-2-methyl-benzoic acid AC-057 2026-48-4 (S)-(+)-2-Amino-3-methyl-1-butanol AC-058 130912-52-6 (+/-)-3-(Aminomethyl)-5-Methylhexanoic acid AC-059 80082-65-1 (2S-trans)-3-amino-2-methyl-4-oxoazetidine-1-sulfonic acid AC-060 96886-55-4 (S)-2-Amino-2-Methyl-4-Pentenoic Acid AC-061 1904-31-0 3-amino-1-methylpyrazole AC-062 17557-67-4 2-Amino-6-methylsulfonylbenzothiazole AC-063 1588-83-6 4-Amino-3-nitro-benzoic acid AC-064 4570-45-0 2-Amino-oxazole AC-065 137281-39-1 4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidi n-5-yl)-ethyl]-benzoic acid AC-066 147027-10-9 (2R,5R)-5-(4-Amino-2-Oxo-2H-Pyrimidin-1-Yl)-[1,3]Oxathio lane-2-Carboxylic Acid,2S-Isopropyl-5-R-Methyl-1R-Cyclohexyl Ester AC-067 5339-85-5 2-amino-phenethylalcohol Hangzhou APIChem Technology Co., Ltd. Email:[email protected]:www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-068 54060-30-9 3-Aminophenylacetylene AC-069 36725-28-7 6-(4-Amino-phenyl)-5-methyl-4,5-dih ydro-2H-pyridazin-3-one AC-070 101328-85-2 (R)-6-(4-Aminophenyl)-5-Methylpyridazin-3(2H)One AC-071 82769-76-4 (S)-3-Amino-3-phenylpropan-1-ol AC-072 13822-56-5 3-Aminopropyltrimethoxysilane AC-073 24242-20-4 5-Amino-2-pyridinecarboxylic acid AC-074 59315-44-5 3-amino-pyridin-2-ol AC-075 86299-47-0 (Z)-2-amino-alpha-[1-(tert-butoxycarbonyl)]-1-1-methyletho xyimino-4-thiazoleacetic acid AC-076 2150-55-2 2-Amino-4-thiazolinic acid AC-077 73150-67-1 2-(2-Aminothiazol-4-yl) glyoxylic acid AC-078 19774-82-4 Amiodarone hydrochloride AC-079 111470-99-6 Amlodipine besylate AC-080 78613-38-4 Amorolfine Hydrochloride AC-081 1156-92-9 4-Androstenediol AC-082 51025-85-5 Arbekacin AC-083 74-79-3 Arginine AC-084 63358-49-6 Aspoxicillin Trihydrate AC-085 156311-83-0 (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate AC-086 112626-50-3 3-Azabicyclo[3.3.0]octane Hydrochloride AC-088 272-49-1 4-Azaindole AC-092 45347-82-8 Azetidin-3-ol AC-093 117772-70-0 Azithromycin AC-094 2446-83-5 Azodicarboxylic Acid Diisopropyl Ester AC-095 4693-47-4 Azopentanon-C AC-096 27589-33-9 Azosemide AC-097 104757-53-1 Barnidipine Hydrochloride AC-098 2390-63-8 Basic violet 11 AC-099 198481-33-3 Bazedoxifene acetate AC-100 195730-31-5 benzocyclobutene-4-boronic acid AC-101 3469-06-5 benzocyclobutenone AC-102 5350-57-2 Benzophenone hydrozone AC-103 3468-01-7 4H-1-Benzopyran-8-carboxylicacid, Hangzhou APIChem Technology Co., Ltd. Email:[email protected]:www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name 3-methyl-4-oxo-2-phenyl- AC-104 89604-91-1 S-2-Benzothiazolyl(Z) -2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyimino thioacetate AC-105 611-73-4 Benzoyl formoic acid AC-106 7697-46-3 2-benzoylpyrrole AC-107 111865-47-5 Benzyl trimethyl ammonium tribromide AC-109 93779-31-8 (S)-Benzyl endo, cis-2-azabicyclo [3,3,0]octanecarboxylate Hydrochloride AC-110 51388-20-6 4-Benzyloxyaniline Hydrochloride AC-114 198479-63-9 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole AC-116 35081-45-9 4'-(Benzyloxy)-2-bromopropiophenone AC-117 2086-83-1 Berberine AC-118 633-65-8 Berberine hydrochloride AC-119 1247-42-3 Betapar AC-120 181695-72-7 Valdecoxib AC-121 120410-24-4 biapenem AC-123 82657-04-3 Bifenthrin AC-124 58-85-5 D-Biotin AC-125 138401-24-8 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl] biphenyl-2-carbonitrile AC-126 16150-45-1 Diethyl cromoglycate AC-128 3197-06-6 N,N-BIS(2-HYDROXYETHYL)ETHYLENEDIAMINE AC-129 5538-94-3 Bisoctyl dimethyl ammonium chloride AC-131 91188-13-5 3-Boc-aminoazetidine AC-132 98737-29-2 (2R,3S)-N-Boc-3-amino-1,2-epoxy-4-phenylbutane AC-133 166104-20-7 1-Boc-5-Aminoindole AC-134 135632-53-0 4-(Boc-aminomethyl) piperidine AC-135 66605-57-0 (S)-2-(Boc-amino)-3-phenyl-1-propanol AC-136 625471-18-3 (S)-N-Boc-3-aminopiperidine AC-137 73286-70-1 N-Boc-2,5-dihydropyrrole AC-138 4530-20-5 N-Boc-L-glycine AC-139 109431-87-0 (R)-N-boc-3-hydropyrrolidine AC-141 13726-69-7 Boc-L-Hyp-OH Hangzhou APIChem Technology Co., Ltd. Email:[email protected]:www.apichemistry.com Email: [email protected] Catalog No. CAS No. Product Name AC-142 147539-41-1 N-Boc-4-methylaminopieridine AC-144 124443-68-1 N-BOC-Piperidine-4-carboxylic acid methyl ester AC-145 35150-07-3 1-Boc-L-prolinamide AC-146 122684-34-8 1-Boc-pyrrolidine-3-carboxamide AC-147 140148-70-5 (S)-1-Boc-pyrrolidine-3-carboxylic acid AC-148 147536-97-8 Bosentan AC-149 91714-93-1 Bromfenac Sodium AC-150 5003-71-4 3-Brominepropylamine hydrobromide AC-151 622-88-8 4-Bromophenylhydrazine Hydrochloride AC-152 139042-59-4 2-BROMO-5-ACETYLPYRIDINE AC-153 615-36-1 2-Bromoaniline AC-154 21120-91-2 1-Bromobenzocyclobutene AC-155 73443-85-3 4-Bromo-3H-benzothiazol-2-one AC-156 19472-74-3 2-bromobenzyl cyanide AC-157 1073-39-8 3-Bromo-bicyclo[4.2.0]octa-1,3,5-triene AC-158 60633-25-2 2-Bromo-4-Chloroanisole AC-159 81682-38-4 2-bromo-5-chlorophenylacetic acid AC-160 36953-42-1 3-Bromo-4-chloropyridine AC-161 68797-61-5 5-Bromo-4,6-dichloropyrimidine AC-162 59803-98-4 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinami ne AC-164 54016-70-5 3-Ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide AC-165 574-98-1 N-(2-Bromoethyl)phthalimide AC-166 133059-43-5 4-Bromo-3-fluorobenzaldehyde AC-167 2252-37-1 2-BROMO-6-FLUOROBENZOIC ACID AC-168 51436-99-8 4-bromo-2-fluorotoluene AC-169 105529-58-6 1-Bromo-2-fluoro-4-(trifluoromethoxy)Benzene AC-170 88139-91-7 5-Bromo-2-hydroxymethylpyridine AC-171 13466-38-1 5-Bromo-2-hydroxypyridine AC-172 34598-49-7 5-Bromo-1-indanone AC-173 14548-39-1 6-Bromo-indan-1-one AC-174 589-87-7 1-Bromo-4-iodobenzene AC-175 2052-01-9 2-Bromoisobutyric acid AC-176 7073-94-1 1-Bromo-2-isopropylbenzene AC-177 2973-59-3 2-Bromo-5-hydroxy-4-methoxybenzaldehyde Hangzhou APIChem Technology Co., Ltd.
Load more

Recommended publications
  • Protective Effects of Rosmarinic Acid Against Selenite-Induced Cataract and Oxidative Damage in Rats Chia-Fang Tsai1,2, Jia-Ying Wu2, Yu-Wen Hsu 3 
    Int. J. Med. Sci. 2019, Vol. 16 729 Ivyspring International Publisher International Journal of Medical Sciences 2019; 16(5): 729-740. doi: 10.7150/ijms.32222 Research Paper Protective Effects of Rosmarinic Acid against Selenite-Induced Cataract and Oxidative Damage in Rats Chia-Fang Tsai1,2, Jia-Ying Wu2, Yu-Wen Hsu 3 1. Department of Applied Cosmetology, National Tainan Junior College of Nursing, Tainan, Taiwan. 2. Department of Biotechnology, TransWorld University, Yunlin County, Taiwan. 3. Department of Optometry, Da-Yeh University, Changhua, Taiwan. Corresponding author: Hsu is to be contacted at the Department of Optometry, Da-Yeh University, No.168, University Rd., Dacun, Changhua 51591, Taiwan. Tel.: +886 4 8511888. E-mail address: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2018.12.12; Accepted: 2019.03.29; Published: 2019.05.10 Abstract Cataracts are the major cause of blindness and are associated with oxidative damage of the lens. In the present study, the aim was to evaluate the protective effects of rosmarinic acid on selenite-induced cataractogenesis in Sprague-Dawley rat pups. The animals were randomly divided into five groups, each of which consisted of 10 rat pups. Group I served as normal control (vehicle administration). For testing cataract induction, animals of Groups II, III, IV, and V were administered a single subcutaneous injection of sodium selenite (2.46 mg/kg body weight) on postpartum day 12.
    [Show full text]
  • Update on Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
    J Bras Pneumol. 2015;41(5):454-466 http://dx.doi.org/10.1590/S1806-37132015000000152 REVIEW ARTICLE Update on diagnosis and treatment of idiopathic pulmonary fibrosis José Baddini-Martinez1, Bruno Guedes Baldi2, Cláudia Henrique da Costa3, Sérgio Jezler4, Mariana Silva Lima5, Rogério Rufino3,6 1. Divisão de Pneumologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brasil. 2. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas, ABSTRACT Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil. Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of 3. Disciplina de Pneumologia e Tisiologia, unknown etiology, which is associated with a progressive decrease in pulmonary Faculdade de Ciências Médicas, function and with high mortality rates. Interest in and knowledge of this disorder have Universidade do Estado do Rio de grown substantially in recent years. In this review article, we broadly discuss distinct Janeiro, Rio de Janeiro, Brasil. aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We 4. Ambulatório de Pneumologia, Hospital list the current diagnostic criteria and describe the therapeutic approaches currently Ana Nery, Salvador, Brasil. available, symptomatic treatments, the action of new drugs that are effective in slowing 5. Ambulatório de Doenças Pulmonares Intersticiais, Hospital do Servidor the decline in pulmonary function, and indications for lung transplantation. Público Estadual de São Paulo, São Keywords: Idiopathic pulmonary fibrosis/diagnosis; Idiopathic pulmonary fibrosis/therapy; Paulo, Brasil. Idiopathic pulmonary fibrosis/rehabilitation. 6. Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0108115 A1 Bringi Et Al
    US 2008O108115A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0108115 A1 Bringi et al. (43) Pub. Date: May 8, 2008 (54) ENHANCED PRODUCTION OF TAXOL AND application No. 08/370,494, filed on Jan. 9, 1995, now TAXANES BY CELL CULTURES OF TAXUS abandoned, which is a division of application No. SPECIES 07/874,344, filed on Apr. 24, 1992, now Pat. No. 5,407, 816, which is a continuation-in-part of application No. (75) Inventors: Venkataraman Bringi, Ithaca, NY 07/839,144, filed on Feb. 20, 1992, now abandoned. (US); Prakash Kadkade, Marlboro, MA (US); Christopher Prince, Lansing, NY Publication Classification (US); Braden Roach, Interlaken, NY (US) (51) Int. Cl. CI2P 17/02 (2006.01) Correspondence Address: (52) U.S. Cl. .............................................................. 435/123 HUNTON & WILLIAMS LLP INTELLECTUAL PROPERTY DEPARTMENT (57) ABSTRACT 1900 KSTREET, N.W. This invention provides methods whereby taxol, baccatin III, SUTE 12OO and other taxol-like compounds, or taxanes, can be produced WASHINGTON, DC 20006-1109 (US) in very high yield from all known Taxus species, e.g., brevi folia, Canadensis, cuspidata, baccata, globosa, floridana, (73) Assignee: DFB BIOTECH, INCORPORATED, wallichiana, media and chinensis. Particular modifications of Fort Worth, TX culture conditions (i.e., media composition and operating modes) have been discovered to enhance the yield of various (21) Appl. No.: 11/836,604 taxanes from cell culture of all species of Taxus. Particularly (22) Filed: Aug. 9, 2007 preferred enhancement agents include silver ion or complex, jasmonic acid (especially the methyl ester), auxin-related Related U.S. Application Data growth regulators, and inhibitors of the phenylpropanoid pathway, Such as 3.4-methylenedioxy-6-nitrocinnamic acid.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • ( 12 ) United States Patent
    US010376507B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 376 , 507 B2 Srinivasan et al. (45 ) Date of Patent: Aug. 13 , 2019 CRESEMBA® ( isavuconazonium sulfate ) , Highlights of Prescrib (54 ) METHOD OF TREATING A PATIENT WITH ing Information , Label ; Patient Information approved by the U . S . A CYP3A4 SUBSTRATE DRUG Food and Drug Administration ; Astellas Pharma US , Inc. ( Licensed from Basilea Pharmaceutics International Ltd . ) , Illinois, USA , Ini (71 ) Applicant: Bow River LLC , Corona Del Mar , CA tial U . S . Approval: 2015 , Revised Mar. 2015 , Reference ID : 3712237, ( US ) 28 pages . DIFLUCAN® ( fluconazole ), Label ; Patient Information , Reference ( 72 ) Inventors : Sundar Srinivasan , Corona Del Mar, ID : 3650838 , Roerig , Division of Pfizer Inc ., New York , NY, Revised Mar. 2013 , 35 pages. CA (US ) ; Christina Chow , Seattle , WA NIZORAL® (ketoconazole )Label ; Patient Information approved by (US ) the U . S . Food and Drug Administration , Reference ID : 3458324 , Copyright 2014 Janssen Pharmaceuticals, Inc . , New Jersey, USA , ( 73 ) Assignee : BOW RIVER LLC , Corona del Mar , Revised Feb . 2014 , 23 pages . NOXAFIL® (posaconazole ) , Highlights of Prescribing Informa CA (US ) tion , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright © 2006 , 2010 , 2013 , 2014 Merck ( * ) Notice : Subject to any disclaimer , the term of this Sharp & Dohme Corp . , a subsidiary of Merck & Co ., Inc ., New patent is extended or adjusted under 35 Jersey , USA , Revised Sep . 2016 , Reference ID : 3983525, 37 pages . U . S . C . 154 (b ) by 0 days. ORAVIG® (miconazole ) , Highlights of Prescribing Information , Label ; Patient Information approved by the U . S . Food and Drug Administration ; Copyright 2012 Praelia Pharmaceuticals , Inc . , North (21 ) Appl.
    [Show full text]
  • TRISTART DHA- Ascorbic Acid, Cholecalciferol, .Alpha
    TRISTART DHA- ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, d-, thiamine hydrochloride, riboflavin, niacin, pyridoxine hydrochloride, levomefolate magnesium, folic acid, cyanocobalamin, iron pentacarbonyl, potassium iodide, magnesium oxide, doconexent, and icosapent capsule, liquid filled CarWin Pharmaceutical Associates, LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- TriStart DHA PRENATAL SUPPLEMENT Supplement Facts Serving Size: 1 Softgel Servings per container: 30 %Daily Value for Amount Per %Daily Pregnant and Serving Value Lactating Women Vitamin C 55 mg 92% 92% (as ascorbic acid) Vitamin D3 1000 IU 250% 250% (as cholecalciferol) Vitamin E 15 IU 50% 50% (as d-alpha-tocopheryl acetate) Thiamin 1.3 mg 87% 76% (as thiamine HCl, Vitamin B1) Riboflavin (Vitamin B2) 1.8 mg 106% 90% Niacin (as nicotinic acid) 5 mg 25% 25% Vitamin B6 35 mg 1750% 1400% (as pyridoxine HCl) Folate (as 630 mcg of L- Methylfolate Magnesium, molar equivalent to 600mcg of L- 1 mg 250% 125% Methylfolic acid; and 400mcg of folic acid) Vitamin B12 14 mcg 233% 175% (as cyanocobalamin) Iron (as carbonyl iron) 31 mg 172% 172% Iodine 200 mcg 133% 133% (as Potassium Iodide) Magnesium 30 mg 8% 7% (as Magnesium Oxide) Docosahexaenoic Acid 200mg * * (DHA) Eicosapentaenoate Acid 15 mg * * (EPA) * Daily Values (DV) not established. OTHER INGREDIENTS: Gelatin (bovine), Glycerin, Purified Water, Yellow Bees Wax, Caramel Powder, Soy Lecithin, Natural Orange Flavor, Ethyl Vanillin. Contains: Soy and Fish TriStart DHA™ Softgel capsules are dye free, lactose, gluten and sugar free.
    [Show full text]
  • Addyi Generic Name: Flibanserin Manufacturer
    Brand Name: Addyi Generic Name: Flibanserin Manufacturer: Sprout Pharmaceuticals Drug Class: Central Nervous System Agent, Serotonin Agonist, Dopamine antagonist Uses: Labeled Uses: Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Unlabeled Uses: none. Mechanism of Action: The mechanism of action for flibanserin in the treatment of hypoactive sexual desire disorder is unknown. Flibanserin has high affinity for serotonin (5-hydroxytryptamine or 5-HT) 1A receptors, as an agonist, and 5-HT2A receptors, as an antagonist, and moderate affinity for 5- HT2B, 5-HT2C, and dopamine D4 receptors as an antagonist Pharmacokinetics: Absorption: Tmax 0.75 hours Vd 50L t ½ 11 hours Clearance Not reported Protein binding 98% (albumin) Bioavailability 33% Metabolism: Flibanserin is extensively metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 to at least 35 metabolites, with most of the metabolites occurring in low concentrations in plasma. Elimination: Flibanserin is primarily excreted through the kidneys in to urine (44%) and feces (51%). Two metabolites could be characterized that showed plasma concentration similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6- hydroxy-flibanserin-6-sulfate. These two metabolites are inactive. Efficacy: Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med.
    [Show full text]
  • Rhynchophylline Loaded-Mpeg-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer's Disease
    International Journal of Nanomedicine Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer’sDisease This article was published in the following Dove Press journal: International Journal of Nanomedicine Ruiling Xu1 Purpose: Alzheimer’s disease (AD) is a growing concern in the modern society. The current Junying Wang1 drugs approved by FDA are not very promising. Rhynchophylline (RIN) is a major active Juanjuan Xu1 tetracyclic oxindole alkaloid stem from traditional Chinese medicine uncaria species, which fi Xiangrong Song2 has potential activities bene cial for the treatment of AD. However, the application of Hai Huang 2 rhynchophylline for AD treatment is restricted by the low water solubility, low concentration in brain tissue and low bioavailability. And there is no study of brain-targeting therapy with Yue Feng 3 RIN. In this work, we prepared rhynchophylline loaded methoxy poly (ethylene glycol)–poly Chunmei Fu1 (dl-lactide-co-glycolic acid) (mPEG-PLGA) nanoparticles (NPS-RIN), which coupled with 1Key Laboratory of Drug-Targeting and Tween 80 (T80) further for brain targeting delivery (T80-NPS-RIN). Drug Delivery System of the Education Methods: Preparation and characterization of T80-NPS-RIN were followed by the detection Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced of transportation across the blood–brain barrier (BBB) model in vitro, biodistribution and Drug and Sichuan Research Center for neuroprotective effects of nanoparticles. Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan Results: The results indicated T80-NPS-RIN could usefully assist RIN to pass through the University, Chengdu 610041, People’s BBB to the brain.
    [Show full text]
  • Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia
    Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia THE TREATMENT OF THE SCHIZOPHRENIA: AN OVERVIEW Gabriella Galizia School of Pharmacy,University of Salerno, Italy e-mail: [email protected] Summary The schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person. The terms antipsychotic and neuroleptic define a group of medicine principally used to treat schizophrenia, but they are also efficacious for other psychosis and in states of psychic agitation. The antipsychotics are divided into two classes: classic or typical and atypical. The paliperidone, the major metabolite of risperidone, shares with the native drug the characteristics of receptoral bond and of antagonism of serotonin (5HT2A) and dopamine (D2). It's available in a prolonged release formulation and it allows the administration once daily. Besides, the paliperidone has a pharmacological action independent of CYT P450 and in such way a lot of due pharmacological interactions would be avoided to interference with the activity of the CYP2D6, that is known to have involved in the metabolism of the 25% of the drugs of commune therapeutic employment. Introduction The schizophrenia has been a very hard disease to investigate by the research. This is not surprising because it involves the most mysterious aspects of human mind, as emotions and cognitive processes. According to scientific conventions, the schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Table S1. The significant drug pairs in potential DDIs examined by the two databases. Micromedex Drugs.com List of drugs paired PK-PD Mechanism details 1. Amiodarone— PD Additive QT-interval prolongation Dronedarone 2. Amiodarone— PK CYP3A inhibition by Ketoconazole Ketoconazole 3. Ciprofloxacin— PD Additive QT-interval prolongation Dronedarone 4. Cyclosporine— PK CYP3A inhibition by Cyclosporine Dronedarone 5. Dronedarone— PK CYP3A inhibition by Erythromycin Erythromycin 6. Dronedarone— PD Additive QT-interval prolongation Flecainide 7. Dronedarone— PK CYP3A4 inhibition by Itraconazole Itraconazole 8. Dronedarone— PK Contraindication Major CYP3A inhibition by Ketoconazole Ketoconazole 9. Dronedarone— PD Additive QT-interval prolongation Procainamide PD 10. Dronedarone—Sotalol Additive QT-interval prolongation 11. Felodipine— PK CYP3A inhibition by Itraconazole Itraconazole 12. Felodipine— PK CYP3A inhibition by Ketoconazole Ketoconazole 13. Itraconazole— PK CYP3A inhibition by Itraconazole Nisoldipine 14. Ketoconazole— PK CYP3A inhibition by Ketoconazole Nisoldipine 15. Praziquantel— PK CYP induction by Rifampin Rifampin PD 1. Amikacin—Furosemide Additive or synergistic toxicity 2. Aminophylline— Decreased clearance of PK Ciprofloxacin Theophylline by Ciprofloxacin 3. Aminophylline— PK Decreased hepatic metabolism Mexiletine 4. Amiodarone— PD Additive effects on QT interval Ciprofloxacin 5. Amiodarone—Digoxin PK P-glycoprotein inhibition by Amiodarone 6. Amiodarone— PD, PK Major Major Additive effects on QT Erythromycin prolongation, CYP3A inhibition by Erythromycin 7. Amiodarone— PD, PK Flecainide Antiarrhythmic inhibition by Amiodarone, CYP2D inhibition by Amiodarone 8. Amiodarone— PK CYP3A inhibition by Itraconazole Itraconazole 9. Amiodarone— PD Antiarrhythmic inhibition by Procainamide Amiodarone 10. Amiodarone— PK CYP induction by Rifampin Rifampin PD Additive effects on refractory 11. Amiodarone—Sotalol potential 12. Amiodarone— PK CYP3A inhibition by Verapamil Verapamil 13.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]